This Company Boosts Interim Dividend 60% -- Here's How its CEO Manages Growth and Shareholder Returns
This Company Has 21% Higher Profit, Record Orders and a Cash Build-up
FUND MANAGER'S VIEW: Small Caps, Great Bargains, and the Power of Patient Capital
This Company Has Mega Mix of Margins, Orders (US$22 Billion), Dividends
iX BIOPHARMA: Will These Upcoming Milestones Re-rate The Stock?